# A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

> **NCT07217015** · PHASE2 · RECRUITING · sponsor: **Kymera Therapeutics, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** KT-621
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07217015
- **Lead sponsor:** Kymera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07217015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07217015, "A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07217015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*